First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Abstract Background Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. Methods Frail patients without prior advanced...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A. Carrato, M. Benavides, B. Massutí, R. Ferreiro-Monteagudo, P. García Alfonso, E. Falcó, M. Reboredo, T. Cano, J. Gallego, J. M. Viéitez, L. Layos, A. Salud, E. Polo, E. Dotor, G. Durán-Ogalla, M. Rodriguez-Garrote, A. Calvo, E. Grande, E. Aranda
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-06-01
coleção:	BMC Cancer
Assuntos:	Regorafenib Colorectal cancer Monotherapy First-line Frail patients Elderly
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-019-5753-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!